Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

详细信息    查看全文

• 作者：Hongwei Zhang ; Ronghua Jin ; Cheng Yao ; Tong Zhang ; Meixia Wang…
• 刊名：AIDS Research and Therapy
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：13
• 期：1
• 全文大小：787 KB
• 参考文献：1.Dolgin E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med. 2014;20(4):323–4.CrossRef PubMed
  2.Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, et al. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother. 2010;54(1):191–6.PubMedCentral CrossRef PubMed
  3.Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE. 2012;7(3):e32599.PubMedCentral CrossRef PubMed
  4.Wu H, Yao C, Lu R, Zhang T, Wang M, Zhao H, et al. Albuvirtide, the first long-acting HIV-1 fusion inhibitor, suppressed viral replication in HIV-infected adults.In: The Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA; Sep 9–12, 2012. Paper H-554.
  5.Cadosch D, Bonhoeffer S, Kouyos R. Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV. J R Soc Interface. 2012;9(74):2309–20.PubMedCentral CrossRef PubMed
  6.Zhang D, Li W, Jiang S. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009–2014). Expert Opin Ther Pat. 2015;25(2):159–73.CrossRef PubMed
  
• 作者单位：Hongwei Zhang (1)
  Ronghua Jin (1)
  Cheng Yao (2)
  Tong Zhang (1)
  Meixia Wang (1)
  Wei Xia (1)
  Haiyan Peng (3)
  Xiaojuan Wang (3)
  Rongjian Lu (2)
  Changjin Wang (2)
  Dong Xie (2)
  Hao Wu (4)
  
  1. Beijing You’an Hospital, Capital Medical University, 100069, Beijing, People’s Republic of China
  2. Nanjing Frontier Biotechnologies Co. Ltd., 5 Qiande Road, Jiangning District, 211122, Nanjing, People’s Republic of China
  3. Beijing Co-CRO Medical Development Co. Ltd., Beijing, People’s Republic of China
  4. Center for Infectious Diseases, Beijing You’an Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai St, Fengtai Dist, 100069, Beijing, People’s Republic of China
  
• 刊物主题：Infectious Diseases; Virology;
• 出版者：BioMed Central
• ISSN：1742-6405

文摘

Background Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11–12 days in human.